Celgene stock's latest leap changes Wall Street's math on Bristol-Myers deal

Bristol-Myers Squibb won endorsements from two key advisory firms on Friday for its acquisition of Celgene, making the deal much more likely to pass muster with shareholders. For holders of Celgene, the endorsements make the stock a little less interesting, because it rose on the news and is now a lot closer to the deal price. That led UBS analyst Carter Gould to downgrade Celgene stock (ticker: CELG) to Neutral from Buy on Monday.